Cytokinetics, Incorporated
CYTK · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $6,594,211 | $3,946,859 | $4,762,354 | $5,554,248 |
| - Cash | $225,467 | $74,940 | $73,680 | $94,857 |
| + Debt | $1,038,106 | $858,058 | $791,055 | $788,677 |
| Enterprise Value | $7,406,850 | $4,729,977 | $5,479,729 | $6,248,068 |
| Revenue | $1,936 | $66,769 | $1,579 | $16,927 |
| % Growth | -97.1% | 4,128.6% | -90.7% | – |
| Gross Profit | -$743 | $64,484 | -$98,262 | -$76,702 |
| % Margin | -38.4% | 96.6% | -6,223.1% | -453.1% |
| EBITDA | -$277,177 | -$107,820 | -$136,130 | -$125,043 |
| % Margin | -14,317% | -161.5% | -8,621.3% | -738.7% |
| Net Income | -$306,178 | -$134,370 | -$161,376 | -$150,020 |
| % Margin | -15,815% | -201.2% | -10,220.1% | -886.3% |
| EPS Diluted | -2.55 | -1.12 | -1.36 | -1.27 |
| % Growth | -127.7% | 17.6% | -7.1% | – |
| Operating Cash Flow | -$107,505 | -$128,236 | -$131,617 | -$65,570 |
| Capital Expenditures | -$9,354 | -$4,145 | -$5,664 | -$1,290 |
| Free Cash Flow | -$116,859 | -$132,381 | -$137,281 | -$66,860 |